Literature DB >> 22609125

Pulmonary delivery of dry powders to rats: tolerability limits of an intra-tracheal administration model.

A Guillon1, J Montharu, L Vecellio, V Schubnel, G Roseau, J Guillemain, P Diot, M de Monte.   

Abstract

The inhaled route is increasingly developed to deliver locally acting or systemic therapies, and rodent models are used to assess tolerance before clinical studies. Endotracheal intubation of rats with a probe which generates powder aerosols enables controlled administration of drug directly into the respiratory tract. However, preliminary observations of intratracheal powder administration procedures have raised concerns with regard to pulmonary safety. The aim of the present work was to evaluate the safety of intra-tracheal administration of dry powder in a rat model. Sixty animals were administered various volumes of air alone, lactose or magnesium stearate through a Microsprayer(®) (Pencentury, USA). The mass of powder actually delivered to each animal was calculated. Rats were sacrificed immediately after administration, and the lungs, trachea and larynx were removed and examined for gross pathology. The mass of powder delivered varied, the full dose being rarely delivered. About one third of the administration procedures resulted in respiratory failure, and macroscopic pulmonary lesions were observed in about 55% of animals. Lung damages were observed with air alone, lactose and magnesium stearate. In conclusion, artifacts observed with this technique may limit the relevance of the model. These observations are particularly important in the context of regulatory toxicity studies.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22609125     DOI: 10.1016/j.ijpharm.2012.05.013

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals.

Authors:  Phillip G Durham; Shumaila N Hanif; Lucia Garcia Contreras; Ellen F Young; Miriam S Braunstein; Anthony J Hickey
Journal:  J Vis Exp       Date:  2017-03-30       Impact factor: 1.355

2.  Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma.

Authors:  Jonathan E Phillips; Lorena Renteria; Lisa Burns; Paul Harris; Ruoqi Peng; Carla M T Bauer; Dramane Laine; Christopher S Stevenson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-04-25       Impact factor: 2.849

3.  Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.

Authors:  Joana Costa-Gouveia; Elisabetta Pancani; Samuel Jouny; Arnaud Machelart; Vincent Delorme; Giuseppina Salzano; Raffaella Iantomasi; Catherine Piveteau; Christophe J Queval; Ok-Ryul Song; Marion Flipo; Benoit Deprez; Jean-Paul Saint-André; José Hureaux; Laleh Majlessi; Nicolas Willand; Alain Baulard; Priscille Brodin; Ruxandra Gref
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

4.  Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System.

Authors:  Jonathan E Phillips; Xuxia Zhang; James A Johnston
Journal:  J Vis Exp       Date:  2017-04-06       Impact factor: 1.355

5.  Systemic Delivery of hGhrelin Derivative by Lyophilizate for Dry Powder Inhalation System in Monkeys.

Authors:  Kahori Miyamoto; Yuko Ishibashi; Tomomi Akita; Chikamasa Yamashita
Journal:  Pharmaceutics       Date:  2021-02-07       Impact factor: 6.321

6.  Evaluation of Phage Therapy for Pulmonary Infection of Mouse by Liquid Aerosol-Exposure Pseudomonas aeruginosa.

Authors:  Yajun Zhang; Biao Meng; Xiao Wei; Yan Li; Xiaohui Wang; Yan Zheng; Changjun Wang; Lihong Cui; Xiangna Zhao
Journal:  Infect Drug Resist       Date:  2021-10-27       Impact factor: 4.003

7.  CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice.

Authors:  Fabio F Stellari; Angelo Sala; Francesca Ruscitti; Carola Buccellati; Andrew Allen; Patrizia Risé; Maurizio Civelli; Gino Villetti
Journal:  Front Pharmacol       Date:  2019-11-12       Impact factor: 5.810

8.  Construction of a Live-Attenuated Vaccine Strain of Yersinia pestis EV76-B-SHUΔpla and Evaluation of Its Protection Efficacy in a Mouse Model by Aerosolized Intratracheal Inoculation.

Authors:  Junxia Feng; Yingying Deng; Mengjiao Fu; Xueyuan Hu; Wenbo Luo; Zhiyu Lu; Lupeng Dai; Huiying Yang; Xiaodong Zhao; Zongmin Du; Bohai Wen; Lingxiao Jiang; Dongsheng Zhou; Jun Jiao; Xiaolu Xiong
Journal:  Front Cell Infect Microbiol       Date:  2020-09-08       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.